• Explore /
  • Poster
  • / Dual antiangiogenic therapy using lenalidomide and bevacizumab with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).

Dual antiangiogenic therapy using lenalidomide and bevacizumab with docetaxel and prednisone in patients with metastatic castration-resistant prostate cancer (mCRPC).

Abstract Poster

Authors

null

Bamidele Adesunloye

Medical Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, MD

Bamidele Adesunloye , Xuan Huang , Yangmin M. Ning , Ravi A. Madan , James L. Gulley , Melony Beatson , Paul Gustav Kluetz , David E. Adelberg , Philip M. Arlen , Howard L. Parnes , Marcia Mulquin , Seth M. Steinberg , John Joseph Wright , Jane B. Trepel , Nancy Ann Dawson , Clara Chen , Carol Bassim , Andrea Borghese Apolo , William Douglas Figg , William L. Dahut

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2012 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Genitourinary (Prostate) Cancer

Track

Genitourinary Cancer

Sub Track

Prostate Cancer

Clinical Trial Registration Number

NCT00942578

Citation

J Clin Oncol 30, 2012 (suppl; abstr 4569)

DOI

10.1200/jco.2012.30.15_suppl.4569

Abstract #

4569

Poster Bd #

23

Abstract Disclosures

Similar Posters

First Author: X. Huang

First Author: Xuan Huang

Poster

2013 Genitourinary Cancers Symposium

Use of supportive measures to improve outcome and decrease toxicity in docetaxel-based antiangiogenesis combinations.

Use of supportive measures to improve outcome and decrease toxicity in docetaxel-based antiangiogenesis combinations.

First Author: Fatima H. Karzai

First Author: Susan Halabi